CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study of Dasatinib added to Standard Chemotherapy for Relapsed/Refractory Ph+ALL

Grant

Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Matthew Kutny M.D.   Principal Investigator